1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by End-Stage Renal Disease (ESRD) Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global End-Stage Renal Disease (ESRD) Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Calcium Succinate
1.4.3 Mk-3866
1.4.4 Pacritinib
1.4.5 Sanguinate
1.4.6 Tesidolumab
1.4.7 Others
1.5 Market by Application
1.5.1 Global End-Stage Renal Disease (ESRD) Drugs Market Share by Application: 2021-2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 ICU
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global End-Stage Renal Disease (ESRD) Drugs Market
1.8.1 Global End-Stage Renal Disease (ESRD) Drugs Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global End-Stage Renal Disease (ESRD) Drugs Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Manufacturers (2015-2020)
2.3 Global End-Stage Renal Disease (ESRD) Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers End-Stage Renal Disease (ESRD) Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Market Share by Region (2015-2020)
3.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Revenue Market Share by Region (2015-2020)
3.3 North America End-Stage Renal Disease (ESRD) Drugs Sales Volume
3.3.1 North America End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.3.2 North America End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia End-Stage Renal Disease (ESRD) Drugs Sales Volume
3.4.1 East Asia End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe End-Stage Renal Disease (ESRD) Drugs Sales Volume (2015-2020)
3.5.1 Europe End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.5.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia End-Stage Renal Disease (ESRD) Drugs Sales Volume (2015-2020)
3.6.1 South Asia End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales Volume (2015-2020)
3.7.1 Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East End-Stage Renal Disease (ESRD) Drugs Sales Volume (2015-2020)
3.8.1 Middle East End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa End-Stage Renal Disease (ESRD) Drugs Sales Volume (2015-2020)
3.9.1 Africa End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.9.2 Africa End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania End-Stage Renal Disease (ESRD) Drugs Sales Volume (2015-2020)
3.10.1 Oceania End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America End-Stage Renal Disease (ESRD) Drugs Sales Volume (2015-2020)
3.11.1 South America End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.11.2 South America End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World End-Stage Renal Disease (ESRD) Drugs Sales Volume (2015-2020)
3.12.1 Rest of the World End-Stage Renal Disease (ESRD) Drugs Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World End-Stage Renal Disease (ESRD) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World End-Stage Renal Disease (ESRD) Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Market Share by Type (2015-2020)
14.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Revenue Market Share by Type (2015-2020)
14.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global End-Stage Renal Disease (ESRD) Drugs Consumption Volume by Application (2015-2020)
15.2 Global End-Stage Renal Disease (ESRD) Drugs Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in End-Stage Renal Disease (ESRD) Drugs Business
16.1 CTI BioPharma Corp
16.1.1 CTI BioPharma Corp Company Profile
16.1.2 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Specification
16.1.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Prolong Pharmaceuticals LLC
16.2.1 Prolong Pharmaceuticals LLC Company Profile
16.2.2 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Specification
16.2.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Merck & Co Inc
16.3.1 Merck & Co Inc Company Profile
16.3.2 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Specification
16.3.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Novartis AG
16.4.1 Novartis AG Company Profile
16.4.2 Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Specification
16.4.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 VESSL Therapeutics Ltd
16.5.1 VESSL Therapeutics Ltd Company Profile
16.5.2 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Specification
16.5.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 End-Stage Renal Disease (ESRD) Drugs Manufacturing Cost Analysis
17.1 End-Stage Renal Disease (ESRD) Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of End-Stage Renal Disease (ESRD) Drugs
17.4 End-Stage Renal Disease (ESRD) Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 End-Stage Renal Disease (ESRD) Drugs Distributors List
18.3 End-Stage Renal Disease (ESRD) Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of End-Stage Renal Disease (ESRD) Drugs (2021-2026)
20.2 Global Forecasted Revenue of End-Stage Renal Disease (ESRD) Drugs (2021-2026)
20.3 Global Forecasted Price of End-Stage Renal Disease (ESRD) Drugs (2015-2026)
20.4 Global Forecasted Production of End-Stage Renal Disease (ESRD) Drugs by Region (2021-2026)
20.4.1 North America End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.4.2 East Asia End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.4.3 Europe End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.4.4 South Asia End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.4.6 Middle East End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.4.7 Africa End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.4.8 Oceania End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.4.9 South America End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World End-Stage Renal Disease (ESRD) Drugs Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Country
21.2 East Asia Market Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Country
21.3 Europe Market Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Countriy
21.4 South Asia Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Country
21.5 Southeast Asia Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Country
21.6 Middle East Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Country
21.7 Africa Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Country
21.8 Oceania Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Country
21.9 South America Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Country
21.10 Rest of the world Forecasted Consumption of End-Stage Renal Disease (ESRD) Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer